We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+17.99%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
-$12.1M
(-1.1%)
Cap. Flow
-$142M
Cap. Flow
% of AUM
-13.41%
Top 10 Holdings %
Top 10 Hldgs %
37.54%
Holding
501
New
15
Increased
262
Reduced
172
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPDR Gold Trust
GLD
|
+$6.54M |
| 2 |
iShares Gold Trust Micro
IAUM
|
+$4.59M |
| 3 |
SPDR Gold MiniShares Trust
GLDM
|
+$3.58M |
| 4 |
Intuit
INTU
|
+$3.2M |
| 5 |
T-Mobile US
TMUS
|
+$2.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$17.2M |
| 2 |
Microsoft
MSFT
|
+$10M |
| 3 |
NVIDIA
NVDA
|
+$9.7M |
| 4 |
Amazon
AMZN
|
+$7.99M |
| 5 |
Broadcom
AVGO
|
+$6.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 38.15% |
| 2 | Healthcare | 22.68% |
| 3 | Communication Services | 12.64% |
| 4 | Consumer Discretionary | 11.62% |
| 5 | Consumer Staples | 3.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ORKA
376
Oruka Therapeutics
ORKA
$7.11B
| $84.3K | 0.01% |
7,520
+11
| +0.1% | +$115 |
|
377
Precigen
PGEN
$2.45B
| $84.2K | 0.01% |
59,286
+542
| +0.9% | +$770 |
|
|
RAPP
378
Rapport Therapeutics
RAPP
$2.29B
| $83.3K | 0.01% |
7,330
-7
| -0.1% | -$74 |
|
|
LKFT
379
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
| $83.3K | 0.01% |
2,976
+45
| +2% | +$1.21K |
|
380
Regenxbio
RGNX
$720M
| $82.7K | 0.01% |
10,075
+137
| +1% | +$1.15K |
|
|
TRML
381
DELISTED
Tourmaline Bio
TRML
| $82.5K | 0.01% |
5,159
+16
| +0.3% | +$259 |
|
382
Kanzhun
BZ
$7.19B
| $82.1K | 0.01% |
4,600
-60,000
| -93% | -$1.01M |
|
383
Savara
SVRA
$1.17B
| $79.1K | 0.01% |
34,714
+290
| +0.8% | +$789 |
|
384
Aura Biosciences
AURA
$802M
| $78K | 0.01% |
12,453
+2,434
| +24% | +$14.2K |
|
385
Pacific Biosciences
PACB
$345M
| $77.1K | 0.01% |
62,190
+5,339
| +9% | +$6.17K |
|
|
ITOS
386
DELISTED
iTeos Therapeutics
ITOS
| $76.6K | 0.01% |
7,687
+359
| +5% | +$2.89K |
|
387
Solid Biosciences
SLDB
$971M
| $75.8K | 0.01% |
15,569
+261
| +2% | +$923 |
|
388
Pulse Biosciences
PLSE
$3.09B
| $75.5K | 0.01% |
5,000
-8,551
| -63% | -$142K |
|
|
TECX
389
Tectonic Therapeutic
TECX
$720M
| $74.5K | 0.01% |
3,750
+791
| +27% | +$16K |
|
390
Erasca
ERAS
$6.45B
| $72.3K | 0.01% |
56,897
+187
| +0.3% | +$250 |
|
391
Arcturus Therapeutics
ARCT
$216M
| $70.9K | 0.01% |
5,447
+14
| +0.3% | +$166 |
|
392
Maravai LifeSciences
MRVI
$861M
| $69.7K | 0.01% |
28,917
+466
| +2% | +$979 |
|
393
Lexicon Pharmaceuticals
LXRX
$1.05B
| $69K | 0.01% |
72,943
+434
| +0.6% | +$281 |
|
394
Rigel Pharmaceuticals
RIGL
$782M
| $67.2K | 0.01% |
3,590
+57
| +2% | +$1.08K |
|
395
Aquestive Therapeutics
AQST
$531M
| $66K | 0.01% |
19,950
+1,661
| +9% | +$4.76K |
|
396
Absci
ABSI
$1.61B
| $65.8K | 0.01% |
25,620
+2,582
| +11% | +$7.27K |
|
397
Prothena Corp
PRTA
$475M
| $65.6K | 0.01% |
10,811
+14
| +0.1% | +$105 |
|
|
TERN
398
DELISTED
Terns Pharmaceuticals
TERN
| $65.4K | 0.01% |
17,541
+504
| +3% | +$1.57K |
|
|
AMRN
399
Amarin Corp
AMRN
$297M
| $65.2K | 0.01% |
4,021
+5
| +0.1% | +$56 |
|
400
Prime Medicine
PRME
$580M
| $65.1K | 0.01% |
26,370
+61
| +0.2% | +$94 |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q2 2025 Portfolio in Review
As of Q2 2025, China Universal Asset Management Company held 501 positions worth $1.06B, down 1.1% from $1.07B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
China Universal Asset Management Company withdrew a net $142M in Q2 2025, closing 24 positions and reducing 172 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $2.81M position sold in full.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 37% a quarter earlier, followed by Healthcare and Communication Services.
Against the trend, China Universal Asset Management Company opened a new position in Tencent Music worth $1.66M.
- China Universal Asset Management Company's largest Q2 2025 buy was Tencent Music: 85,000 shares worth $1.66M.
- China Universal Asset Management Company added most to SPDR Gold Trust in Q2 2025, an estimated $6.54M increase.
- China Universal Asset Management Company's biggest Q2 2025 reduction was Apple, cutting an estimated $17.2M.
- China Universal Asset Management Company fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $2.81M.
- China Universal Asset Management Company's ten largest holdings make up 38% of its $1.06B portfolio in Q2 2025.
- China Universal Asset Management Company opened 15 new positions and closed 24 in Q2 2025.
- China Universal Asset Management Company's portfolio value fell 1.1% quarter-over-quarter to $1.06B.
Based on China Universal Asset Management Company's 13F filing for Q2 2025, filed 28 Aug 2025.